Table 5.
Relative expression of genes selectively modulated in Post- vs Pre-CPB ASD samples
| Function | Gene symbol | Gene description | Fold changea |
|---|---|---|---|
| Inflammatory response | KDR (FLK1, VEGFR) | Kinase insert domain receptor (type III receptor tyrosine kinase), VEGF receptor | 0.5 |
| C4A/C4B | Complement component 4A (Rodgers blood group)/4B (Chido blood group) | 0.4 | |
| CFIv | Complement factor I | 0.3 | |
| CFB | Complement factor B | 0.2 | |
| SLPI | Secretory leukocyte peptidase inhibitor | 0.2 | |
| Cell adhesion | PTPRF | Protein tyrosine phosphatase, receptor type, F | 0.4 |
| FLRT3 | Fibronectin leucine rich transmembrane protein 3 | 0.2 | |
| MSLN | Mesothelin | 0.16 | |
| PRG4 | Proteoglycan 4 | 0.13 | |
| Oxidative stress | PTGIS | Prostaglandin I2 (prostacyclin) synthase | 0.5 |
| AOX1 | Aldehyde oxidase 1 | 0.5 |
Comparative analysis of gene expression in Pre-CPB and Post-CPB ToF samples was conducted as described in “Methods” section. A main function, a gene symbol, a brief gene description, and the fold change values are specified for each gene
Genes for each functional category are ordered according to decreasing fold changes
aFold change was calculated as the ratio between the mean expression value of Post-ToF and Pre-ToF samples for each gene. Fold changes ≥ 2 or ≤ 0.5 are considered significant